Table 6.
Univariable and multivariable Cox proportional hazards regression for overall survival with HPV16+ 350T and 350G in the CANUSA cohort.
| Variable | Univariable Analysis | Multivariable Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| Age at diagnosis | 1.02 (0.97–1.07) | 0.423 | ||
| Sex | ||||
| Male vs. Female | 0.41 (0.12–1.32) | 0.134 | ||
| Subsite | ||||
| Tonsil vs. base-of-tongue | 0.74 (0.22–2.52) | 0.629 | ||
| Other vs. base-of-tongue | 1.06 (0.19–5.77) | 0.950 | ||
| T stage | ||||
| T3–T4 vs. T1–T2 | 4.62 (1.27–16.8) | 0.020 | ||
| N stage | ||||
| N2–N3 vs. N0–N1 | 0.43 (0.14–1.27) | 0.126 | ||
| Overall Stage | ||||
| III–IV vs. I–II | 7.59 × 107 (0–Inf) | 0.998 | 4.62 (1.27–16.8) | 0.020 |
| Smoking status | ||||
| Former vs. Never | 0.47 (0.09–2.40) | 0.360 | ||
| Current vs. Never | 1.35 (0.41–4.45) | 0.620 | ||
| Smoking Frequency | ||||
| Light vs. Never | 0.66 (0.13–3.40) | 0.619 | ||
| Heavy vs. Never | 1.05 (0.32–3.45) | 0.938 | ||
| HPV16 T350G | ||||
| 350G vs. 350T | 2.91 (0.89–9.46) | 0.076 | ||
| Treatment | ||||
| Chemotherapy + Radiation | 8.98 × 10−1 (0.27–2.95) | 0.859 | ||
| Surgery + Chemotherapy + Radiation | 1.29 × 10−8 (0–Inf) | 0.999 | ||
| Surgery + Radiation | 1.30 × 10−8 (0–Inf) | 0.999 | ||
| Surgery Alone | 1.11 (0.34–3.66) | 0.859 | ||
| Radiation Alone | 1.29 × 10−8 (0–Inf) | 0.999 | ||
p ≤ 0.05 are in red.